Theravance Biopharma (TBPH) Convertible Debt (2016 - 2022)

Theravance Biopharma (TBPH) has 7 years of Convertible Debt data on file, last reported at $228.6 million in Q2 2022.

• On a quarterly basis, Convertible Debt changed 0.47% year-over-year to $228.6 million in Q2 2022; TTM through Jun 2022 was $228.6 million, a 0.47% change from a year earlier, with the FY2021 full-year figure at $228.0 million, changed 0.47% from the prior year.
• Convertible Debt for Q2 2022 stood at $228.6 million, roughly flat from $228.3 million in the prior quarter.
• Over the last five years, Convertible Debt for TBPH reached as high as $228.6 million in Q2 2022 and fell as low as $224.0 million in Q1 2018.
• Historically, Convertible Debt has averaged $226.3 million across 5 years, with a median of $226.3 million in 2020.
• Across the five-year window, Convertible Debt advanced 0.48% in 2018 and gained 0.47% in 2022, its largest moves.
• Year by year, Convertible Debt stood at $224.8 million in 2018, then rose by 0.48% to $225.9 million in 2019, then climbed by 0.48% to $227.0 million in 2020, then advanced by 0.47% to $228.0 million in 2021, then advanced by 0.24% to $228.6 million in 2022.
• Per Business Quant data, the three most recent Convertible Debt figures were $228.6 million in Q2 2022, $228.3 million in Q1 2022, and $228.0 million in Q4 2021.